Neil Pravin Shah, MD

Professor

Hematology and Oncology, Hematology and Oncology UCSF Health

Education
M.D., 1996 - School of Medicine, University of California Los Angeles
Websites
Publications
  1. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
  2. Product review on the Anti-PD-L1 antibody atezolizumab.
  3. Assessing Screening Guidelines for Cardiovascular Disease Risk Factors using Routinely Collected Data.
  4. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
  5. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
  6. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
  7. Cow's Milk Allergy Prescribing Is Influenced by Regional and National Guidance.
  8. PPAR?: Welcoming the New Kid on the CML Stem Cell Block.
  9. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
  10. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
  11. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
  12. Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia.
  13. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
  14. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
  15. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
  16. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or int
  17. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
  18. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
  19. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
  20. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
  21. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
  22. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
  23. Advanced CML: therapeutic options for patients in accelerated and blast phases.
  24. Progressive thoughts about progressive disease.
  25. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
  26. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
  27. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
  28. Dasatinib.
  29. Medical management of CML.
  30. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
  31. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
  32. Gene expression changes associated with progression and response in chronic myeloid leukemia.
  33. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
  34. Dynamics of chronic myeloid leukaemia.
  35. Loss of response to imatinib: mechanisms and management.
  36. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
  37. Overriding imatinib resistance with a novel ABL kinase inhibitor.
  38. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
  39. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
  40. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.